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ABSTRACT
Classifying adult gliomas remains largely a histologic diagnosis based on 
morphology; however astrocytic, oligodendroglial and mixed lineage tumors can display 
overlapping histologic features. We used multiplexed exome sequencing (OncoPanel) 
on 108 primary or recurrent adult gliomas, comprising 65 oligodendrogliomas, 28 
astrocytomas and 15 mixed oligoastrocytomas to identify lesions that could enhance 
lineage classification. Mutations in TP53 (20/28, 71%) and ATRX (15/28, 54%) were 
enriched in astrocytic tumors compared to oligodendroglial tumors of which 4/65 
(6%) had mutations in TP53 and 2/65 (3%) had ATRX mutations. We found that 
oligoastrocytomas harbored mutations in TP53 (80%, 12/15) and ATRX (60%, 9/15) 
at frequencies similar to pure astrocytic tumors, suggesting that oligoastrocytomas 
and astrocytomas may represent a single genetic or biological entity. p53 protein 
expression correlated with mutation status and showed significant increases in 
astrocytomas and oligoastrocytomas compared to oligodendrogliomas, a finding 
that also may facilitate accurate classification. Furthermore our OncoPanel analysis 
revealed that 15% of IDH1/2 mutant gliomas would not be detected by traditional 
IDH1 (p.R132H) antibody testing, supporting the use of genomic technologies in 
providing clinically relevant data. In all, our results demonstrate that multiplexed 
exome sequencing can support evaluation and classification of adult low-grade 
gliomas with a single clinical test.
INTRODUCTION
Adult gliomas account for 20% of primary brain 
tumors, comprising a spectrum of tumors with varying 
grades (WHO Grade I-IV) and dramatic differences in 
patient outcomes and survival [1]. Glioblastoma (GBM, 
WHO Grade IV) is the most common primary malignant 
brain tumor of adults accounting for 54% of all gliomas Oncotarget 8084 www.impactjournals.com/oncotarget
with a median survival of 15 months despite surgical and 
chemo-radiotherapeutic intervention [2, 3]. Although 
large-scale systematic efforts have vastly expanded our 
knowledge of the underlying biology and genetics of 
GBM, adult lower grade gliomas (ALGGs) (WHO Grade 
II and III), including oligodendrogliomas, astrocytomas 
and mixed gliomas (oligoastrocytomas) remain less 
studied. Importantly several recent reports have broadened 
our understanding of these tumors and highlighted the 
utility of large scale sequencing studies in identifying 
clinically distinct subgroups [4, 5]. These lower grade, 
infiltrating gliomas represent 15% of all primary brain 
tumors diagnosed in adults and typically manifest in 
younger patients (3rd and 4th decades) compared to GBMs 
which occur later in life (5th-7th decades) [6-9]; however 
ALGGs can progress to higher grade lesions with 
resistance to standard of care therapies including radiation 
and chemotherapy. 
Gliomas comprise a heterogeneous group of 
brain  tumors  traditionally  classified  by  morphologic 
features ascribed to normal non-neoplastic cells in the 
brain such as astrocytes and oligodendrocytes. The 
current grading criteria for gliomas rely primarily on 
histopathologic features. Typically WHO Grade II 
gliomas have moderate cellularity and nuclear atypia 
with low mitotic indices, whereas Grade III astrocytic 
tumors show increasing atypia and mitoses. Additionally 
anaplastic oligodendrogliomas and oligoastrocytomas 
can present with vascular proliferation and necrosis [10]. 
Distinguishing tumor lineage on histologic criteria alone 
is challenging as tumors frequently have overlapping 
morphologic features. Although immunohistochemistry is 
routinely used to assist in distinguishing tumor lineage, it 
is also not definitive or reproducible. Indeed diagnostic 
classification  of  oligoastrocytomas  is  associated  with 
an inter-observer variability rate approaching 50%, 
demonstrating the need for objective biomarkers to aid     
prognostic and therapeutic decision-making [11, 12].
To support diagnosis and classification of ALGGs, 
significant effort has been made to identify lineage-specific 
molecular and genetic markers. Indeed the presence of 
chromosome 1p and 19q deletions (1p/19q co-deletion) 
determined by FISH or array comparative genomic 
hybridization (aCGH) is currently used to support the 
diagnosis of oligodendrogliomas, as this event occurs in 
>90% of cases [13]. Mutations in isocitrate dehydrogenase 
1 and 2 genes (IDH1/2) have been identified in >80% of 
ALGGs as well as a subset of GBMs that progressed 
from lower grade gliomas [14, 15]. IDH1/2 mutations 
are the most frequent mutations detected in lower grade 
gliomas and those tumors associated with IDH1/2 
mutation are reported to have better outcomes compared 
to wild type tumors [14]. IDH1/2 catalyze the oxidative 
decarboxylation of isocitrate to produce α-ketoglutarate (α-
KG). Mutant IDH1/2 enzymes gain neomorphic functions 
that result in the production of the putative oncometabolite 
2-Hydroxyglutarate (2HG) from α-KG;  however,  the 
precise mechanism by which IDH1/2 mutations promote 
tumorigenesis remains to be elucidated including other 
cooperating genomic events that are required for cellular 
transformation [16]. The presence of IDH1/2 mutations in 
both astrocytomas and oligodendrogliomas suggests that 
this mutation occurs early in glioma development, most 
likely in a stem/progenitor cell that can give rise to both 
cell types [14]. 
Distinguishing between astrocytic, oligodendroglial 
and mixed lineage gliomas based on morphologic 
and immunohistochemical features continues to be 
challenging. Accurate determination of lineage is essential 
in prognostication and treatment planning for patients. 
With next generation sequencing rapidly integrating into 
the clinical and clinical research setting, we profiled a 
cohort of 108 ALGGs as part of a clinical research program 
in a CLIA certified laboratory in order to demonstrate the 
utility of multiplexed exome sequencing as an adjunct 
to  traditional  methods  of  brain  tumor  classification. 
Furthermore we sought to determine whether targeted 
sequencing might reliably and simultaneously capture 
known mutations with prognostic significance, identify 
patients who may benefit from targeted therapies and help 
re-envision a modern classification system for ALGGs 
incorporating histologic and molecular data to improve 
inter-observer reliability for diagnosis of these challenging 
tumors. 
RESULTS
TP53 and ATRX mutations frequently co-occur 
in astrocytic and mixed lineage tumors but not in 
oligodendrogliomas
To map mutational signatures of ALGGs across 
astrocytic, mixed and oligodendroglial lineages we 
established  a  cohort  of  108  tumors  and  performed 
multiplexed exome sequencing using the OncoPanel 
platform, which covers 275 cancer related genes. The 
ALGG cohort consisted of 10 diffuse astrocytomas (DA2, 
WHO Grade II), 18 anaplastic astrocytomas (AA3, WHO 
Grade III), seven oligoastrocytomas (OA2, WHO Grade 
II), eight anaplastic oligoastrocytomas (OA3, WHO Grade 
III), 44 oligodendrogliomas (O2, WHO Grade II) and 21 
anaplastic oligodendrogliomas (O3, WHO Grade III). 
Tumors  were  classified  by  lineage  following 
independent pathologist review (SHR, JBC) and then 
correlated with frequently mutated genes. The most 
common mutations across the ALGG cohort were IDH1 
and IDH2, which collectively occurred in 90% (97/108) 
of tumors suggesting that formation of these neomorphic 
metabolic enzymes represents an early event in 
gliomagenesis. Examination of lineage specific mutations Oncotarget 8085 www.impactjournals.com/oncotarget
showed a predominance of TP53 mutations in astrocytic 
(71%, 20/28) and mixed lineage (80%, 12/15) tumors 
(Figure 1A, Supplemental Table 1-4). ATRX mutations 
were similarly restricted to astrocytic and mixed lineag 
tumors with a frequency of 54% (15/28) and 60% (9/15), 
respectively. Interestingly, all ATRX mutations co-occurred 
with TP53 mutations in these tumors, suggesting that 
TP53 mutations preceded ATRX alterations. The frequency 
of TP53 and ATRX mutations were independent of tumor 
grade as both Grade II and III tumors exhibited similar 
mutation rates among astrocytic and mixed lineage tumors 
(Figure 1B, C).
In contrast TP53 and ATRX mutations were rare 
in oligodendroglial tumors (Figure 1A, Supplemental 
Table 5-6). Of the 44 tumors independently assigned O2 
diagnoses, only one sample contained an ATRX mutation, 
while TP53 mutations were not detected. Comparatively, 
in O3 tumors we found only one sample (1/21) harbored an 
ATRX mutation while TP53 mutations were more frequent 
(19%, 4/21) (Figure 1B). These findings suggest that in 
oligodendroglial tumors TP53 mutations are more likely 
to be later events where they may function to mediate 
progression or resistance to therapy, while in astrocytic 
and mixed lineage tumors TP53 and ATRX lesions are 
often early genetic events along with IDH1 mutations. 
To further explore the implications of somatic mutations 
as markers of genomic progression, individual ALGG 
patients with multiple resections should be analyzed to 
compare genomic changes with histologic progression 
from low to high grade gliomas.
Protein analysis of p53 and ATRX demonstrates 
differential expression across tumor lineages
To determine whether p53 and ATRX protein levels 
correlate with mutation status or glioma lineage, we 
performed immunohistochemistry on a subset of patient 
samples. We found that p53 nuclear positivity was high 
in DA2, AA3 and OA3 tumors but present at low levels 
in oligodendroglial tumors (Figure 2A). 25% of DA2, 
34% of AA3, 7% of OA2 and 63% of OA3 had high 
levels of p53 in the nucleus, whereas oligodendroglial 
tumors demonstrated significantly lower levels of nuclear 
Figure 1: (A, B) Oncoprint diagramming TP53, ATRX and PTEN mutational status from 108 ALGGs categorized by 
lineage (A) or WHO grade (B). Gray boxes represent individual tumors and green boxes indicate presence of a mutation. (C) Table 
summarizing TP53, ATRX and PTEN mutations occurring singly or in combination across all tumor classes.Oncotarget 8086 www.impactjournals.com/oncotarget
p53 (2.3% in O2, 2.7% in O3) (Supplemental Figure 
1A). When comparing p53 levels between grade II and 
III tumors within the same lineage, we found that only 
mixed lineage tumors showed a statistically significant 
(p<0.0001) increase in p53 levels in higher-grade tumors. 
Consistent with high frequencies of wildtype ATRX 
in oligodendroglial tumors, ATRX protein expression was 
high in these tumors while astrocytic and mixed lineage 
tumors in which ATRX is frequently mutated (loss of 
function events) exhibited low protein levels. ATRX 
was present in the nucleus of 61% and 79% of O2 and 
O3, respectively, but in the nucleus of only 3%, 31%, 
1% and 36% of DA2, AA3, OA2 and OA3, respectively 
(Supplemental  Figure  1B).  Our  findings  also  showed 
ATRX protein levels were significantly increased in grade 
III tumors compared to grade II across all lineages. 
Correlative analysis between glioma lineage and 
protein levels showed p53 levels were significantly higher 
in astrocytic and mixed lineage tumors compared to 
oligodendroglial tumors while the opposite was true for 
ATRX; oligodendroglial tumors expressed higher ATRX 
levels compared to astrocytic and mixed lineage tumors 
(Figure 2B, C). Furthermore when we compared p53 levels 
to TP53 mutational status we found that tumors with TP53 
mutations were significantly more likely to express p53 
protein (Figure 2D). In contrast, ATRX protein expression 
was independent of ATRX mutation status (Figure 2E). 
Taken  together  these  findings  suggest  that 
protein analysis of p53 and ATRX in ALGGs support 
our hypothesis that astrocytic and mixed lineage 
tumors depend on loss of p53 and ATRX functions 
while oligodendroglial tumors are driven by alternate 
Figure 2: (A) Representative H&E, p53 and ATRX images from IHC analysis on tumors from each diagnostic category. 
(B) Quantification of p53 demonstrates significant increases in nuclear positivity in astrocytic and mixed lineage tumors compared to 
oligodendroglial tumors, while ATRX expression is significantly increased in oligodendrogliomas (C). (D) p53 expression significantly 
correlated with TP53 mutations whereas ATRX expression was independent of mutation status across ALGG cohort (E). Oncotarget 8087 www.impactjournals.com/oncotarget
mechanism(s). 
Spectrum of IDH mutations in adult lower grade 
gliomas reveals the utility of exome sequencing
As previously described our cohort of ALGGs 
demonstrated a high frequency of IDH1/2 mutations; 
however the spectrum of mutations was diverse and 
highlighted the need for integration of sequencing 
based assays into routine diagnostics. At present, the 
standard method for detecting IDH1 mutations is by 
immunohistochemistry (IHC) using an antibody specific 
for the IDH1  p.R132H variant. Since the OncoPanel 
sequencing platform includes IDH1 and IDH2, we sought 
to characterize the spectrum of IDH1/2 mutations given 
the important clinical and prognostic implications of 
IDH1/2 mutations in gliomas. As demonstrated in Figure 
3A, 90% (97/108) of tumors in our cohort harbored either 
an IDH1 or IDH2 mutation. When analyzed by lineage, 
100% (65/65) of pure oligodendroglial tumors contained 
IDH1/2 mutations while 64.3% and 93.3% of astrocytic 
and mixed lineage tumors were positive for IDH1/2 
mutations, respectively (Figure3C). Interestingly IDH2 
mutations were restricted to oligodendroglial tumors 
with a similar distribution between O2 and O3. The 
Figure 3: (A, B) Oncoprint diagramming IDH1 and IDH2 mutational status from 108 ALGGs categorized by lineage 
(A) or WHO grade (B). (C) Table summarizing IDH1 and IDH2 mutations across all tumor classes. (D) Graph representing frequency 
of IDH1 and IDH2 variants in each diagnostic category. Oncotarget 8088 www.impactjournals.com/oncotarget
most common mutation identified was IDH1 p.R132H, 
which occurred in the majority of tumors independent 
of lineage or grade (Figure 3C, D); however we found 
that over 13.9% (15/108) of tumors harbored non-IDH1 
p.R132H variants or IDH2 mutations, which would not 
be detected by traditional IHC analysis. Among DA2s 
IDH1 p.R132L or p.R132C accounted for 20% of IDH1 
mutations (n=1, 1 respectively) while 11% of AA3s 
harbored  IDH1 p.R132C or p.R132S mutations. This 
was similar for mixed lineage tumors that presented with 
13.3% (2/15) IDH1 p.R132L and p.R132C mutations. 
Furthermore despite the high frequency of IDH1 p.R132H 
mutations detected in oligodendroglial tumors, we found 
that 13.6% (6/44) of O2s had IDH2, IDH1 p.R132G or 
IDH1 p.R132S mutations. Similarly 14.3% (3/21) of O3 
tumors in our cohort harbored IDH2 p.R172K or p.R172W 
mutations. In sum, a total of 13.9% (15/108) IDH1/2 
mutant tumors in our ALGG cohort would have eluded 
detection if relying solely on traditional IDH1 p.R132H 
immunohistochemistry.
IDH1/2 negative adult low-grade gliomas enrich 
for EGFR mutations and amplifications
As expected IDH mutations were the most 
prevalent lesion in our ALGG cohort; however, 10% of 
tumors (11/108) were negative for IDH1/2 mutations, 
including three DA2s, one OA2 and seven AA3s. To 
determine whether these tumors harbored unique or 
unifying lesions, we expanded our analysis to assess copy 
number alterations as well as somatic mutations. Of the 
seven AA3 tumors, three contained EGFR amplification 
with monosomy 10 or CDKN2A/B deletion, a pattern 
more typical of GBM than ALGG suggesting that these 
tumors may in fact be more clinically aggressive than 
typical AA3s or under-sampled with respect to the 
overall features of the tumor (Figure 4). The remaining 
four AA3s lacked EGFR amplification but were positive 
for  EGFR  mutations  (p.V774M,  p.G598V,  p.L861Q, 
p.R108K, p.G449V). Similarly two DA2s harbored EGFR 
(p.V301del) and PTEN (p.G165R) mutations respectively, 
whereas the third DA2 harbored the oncogenic FGFR1 
p.K656E mutation, which has recently been implicated in 
pediatric GBMs and pontine gliomas [17, 18]. The single 
IDH1/2 wildtype OA2 showed PIK3R1 p.EY451del, and 
a frameshift mutation (p.E76fs) in the cancer associated 
phosphatase PTPN11 gene. These analyses highlight the 
utility of multiplexed exome sequencing in detecting 
tumors most likely to follow a more aggressive clinical 
path as well as potential therapeutic targets. 
DISCUSSION
Clinical use of next-generation sequencing 
technologies represents a complementary data stream 
that can serve as an aid to improve the reproducibility of 
diagnosis and classification of primary brain tumors. Here 
we report our findings from analyzing multiplexed exome 
sequencing data generated in a CLIA-certified clinical 
laboratory for integration into diagnostic pathology. 
Traditionally, the diagnosis of ALGGs has relied solely on 
W.H.O. criteria for morphologic features identified by light 
microscopy. While advances in immunohistochemical 
and molecular assays have supplemented this gold 
standard approach, we demonstrate how incorporation of 
sequencing data could readily improve tumor diagnosis 
and classification, thereby making it the next step in the 
evolution of pathological classification of brain tumors 
(Figure 5). 
Our  analysis  of  108  ALGGs  encompassing 
astrocytic, mixed and oligodendroglial lineage tumors 
revealed that TP53 mutations were most frequent in 
astrocytic and mixed lineage tumors but were rarely 
present in oligodendroglial tumors and when present were 
Figure 4: Table summarizing copy number alterations and mutations in IDH1/2 wildtype ALGGs.Oncotarget 8089 www.impactjournals.com/oncotarget
only seen in anaplastic oligodendrogliomas, consistent 
with  previous  studies  [19].  These  findings  suggest 
that early events in the formation of oligodendroglial 
tumors include IDH1/2 mutations in association 
with 1p/19q co-deletion, FUBP1 and CIC mutations 
but not TP53 mutations. When present in anaplastic 
oligodendrogliomas,  TP53 mutations may represent a 
marker of progression and/or resistance to therapies, 
which is supported by previous studies showing that TP53 
mutations in malignant gliomas are a primary mechanism 
leading to radio-resistance [20]. Similarly, ATRX mutations 
were also enriched in astrocytic and mixed lineage 
tumors but only 2/65 oligodendroglial tumors contained 
ATRX mutations. When ATRX mutations were present in 
astrocytic and mixed lineage gliomas, they always (100%) 
co-occurred with TP53 mutations. These findings suggest 
that (1) TP53 mutations occur prior to developing ATRX 
mutations in astrocytic and mixed lineage gliomas and, (2) 
TP53 mutations predispose a tumor to developing ATRX 
mutations, which may further accelerate tumorigenesis. 
To further assess the relevance of p53 and ATRX as 
distinguishing biomarkers among ALGGs we performed 
immunohistochemistry on a subset of tumors and showed 
that  p53  is  expressed  at  significantly  lower  levels  in 
oligodendroglial tumors compared to astrocytic and 
mixed gliomas. In fact, TP53 mutated tumors significantly 
correlated with increased protein expression, which is 
consistent with high protein expression in astrocytic 
and mixed lineage tumors. Conversely oligodendroglial 
tumors demonstrated significantly increased ATRX protein 
expression compared to astrocytic and mixed lineage 
tumors, however ATRX mutations were not correlated 
with ATRX expression, consistent with previously 
published  studies  [21,  22].  Together  these  findings 
suggest that IHC analysis will provide valuable, real time 
adjuncts to pathologic classification of ALGGs wherein 
oligodendrogliomas are more likely to have high ATRX 
protein levels in conjunction with low p53 expression and 
positive IDH1 p.R132H staining.
We investigated the spectrum of IDH1/2 mutations 
in ALGGs given their critical role as prognostic indicators 
for a more favorable clinical course compared to IDH 
wildtype gliomas. The current standard-of-care assay in 
clinical labs is to perform IHC for IDH1 p.R132H, the 
most common variant among IDH1 mutations. In our 
study we demonstrated that among the 97 IDH1/2 mutated 
ALGGs in our cohort, 17% (15/97) would not have been 
detected by IHC against IDH1 p.R132H. In fact, 10% of 
O2s and 20% of O3s were positive for IDH2 mutations 
and negative for IDH1 mutations. Given the clinical value 
of identifying IDH1/2  mutated  gliomas,  our  findings 
provide a compelling reason to advance IDH1 p.R132H 
protein negative ALGGs for exome or targeted sequencing 
of IDH1/2.
Although the prevalence of IDH1/2 mutations 
among ALGGs was high (90%), it suggests that for the 
remaining 10% of IDH1/2 wildtype tumors an alternate 
mechanism might be attributed to gliomagenesis. In fact, 
among the seven IDH1/2 wildtype AA3s, 3 harbored 
polysomy 7 with EGFR amplification and monosomy 
10, a pattern of genomic aberrations more consistent 
with GBM rather than AA3. These findings suggest that 
a subset of IDH1/2 wildtype AA3 tumors may represent 
(1) under sampled GBMs or (2) incipient GBMs that have 
not yet developed the morphologic criteria (microvascular 
proliferation and/or necrosis) sufficient to be designated 
as WHO Grade IV. The four other IDH1/2 wildtype AA3s 
each harbored varying EGFR mutations in combination 
with other gene variants (e.g. PTEN, TP53, PDGFRA) 
suggesting an alternate mechanism to gliomagenesis. 
The judicious integration of next-generation 
sequencing  analysis  into  the  classification  of  brain 
tumors based on our studies represents an opportunity to 
improve diagnosis and reproducibility of glioma lineage 
classification across institutions. In fact our study suggests 
tighter correlations with histology are possible than in 
prior studies where histologic assignments may have been 
less strict or may not have involved re-review of diagnoses 
included in the genomic analysis. The findings highlighted 
in this study provide insights into how this new integrated 
Figure 5: Schematic proposing an integrated classification for distinguishing ALGGs utilizing IDH1/2, TP53, ATRX 
and EGFR mutation status.Oncotarget 8090 www.impactjournals.com/oncotarget
schema would work for ALGGs by combining traditional 
histopathology, molecular and sequencing data to 
classify ALGGs (Figure 5). Based on our data, following 
histopathology review, tumors classified along the ALGG 
spectrum including WHO Grades II and III astrocytomas, 
oligodendrogliomas and mixed tumors could be initially 
divided based on IDH1/2 mutations into mutant and 
wildtype groups. For institutions without the ability to 
perform exome sequencing, there still remains a critical 
need to determine IDH1/2 mutational status among ALGG 
patients; therefore rapid PCR assays, targeting IDH1 
codon 132 and IDH2 codon 172, could serve as a feasible 
alternative.
As the majority of ALGGs are likely to be IDH1/2 
mutated, oligodendroglial tumors can be readily identified 
by the presence of 1p/19q co-deletion, mutations in 
CIC and FUBP1, and high ATRX with low p53 protein 
expression. Astrocytomas and oligoastrocytomas would 
most often harbor mutations in TP53, ATRX and PTEN 
and show high p53 with low ATRX protein expression. 
In fact, based on the diagnostic challenges distinguishing 
astrocytomas  from  oligoastrocytomas,  our  findings 
suggested that these tumors are likely morphologic 
variants belonging in a single category. This hypothesis is 
supported by the nearly identical frequencies and patterns 
of TP53, ATRX and PTEN mutations; however a greater 
number of tumors, especially oligoastrocytomas, will need 
to be analyzed in order to fully define the relationship 
between astrocytomas and mixed gliomas. Based on 
our findings astrocytomas and mixed tumors could be 
classified  simply  as  Diffuse  Glioma  (IDH1/2 mutant) 
WHO II or Anaplastic Diffuse Glioma (IDH1/2 mutant) 
WHO Grade III based on traditional glioma grading 
criteria. 
ALGGs found to lack IDH1/2 mutations need to 
be thoroughly re-investigated with integration of clinical, 
surgical and neuroimaging data to ensure adequate 
sampling of the patients’ tumors. Three of 7 AA3s in 
our cohort showed evidence of EGFR  amplification, 
monosomy 10 and CDKN2A/B deletion a pattern 
more typical of GBM rather than ALGG. Therefore, as 
sequencing and genomic data become integrated into 
routine pathology diagnostics, such tumors may need to 
be evaluated as to whether molecular upgrading to GBM 
is warranted even when overt necrosis or microvascular 
proliferation are not present on light microscopy. 
Alternatively,  IDH1/2 wildtype ALGGs that lack a 
genomic GBM signature should be evaluated for other 
potential oncogenic drivers, including mutations such as 
FGFR1 p.K656E, which has been identified in pediatric 
gliomas. As such, these patients may benefit from early 
intervention with targeted inhibitors in combination with 
traditional therapies such as temozolomide.
In addition to providing complimentary data for 
ALGG classification, targeted exome sequencing may also 
prove valuable in guiding therapeutic decision making. 
With open clinical trials for IDH1 mutant glioma patients, 
determining IDH1 mutational status for ALGG patients is 
critical for satisfying trial entry criteria. Similarly, as IDH2 
inhibitors currently in trial for hematologic malignancies 
open for glioma patients, sequencing remains the only 
method of identifying eligible patients. Furthermore 
as studies have shown that IDH1/2 mutant gliomas 
have a favorable prognosis compared to their wildtype 
counterparts, excluding or controlling for these patients 
in GBM clinical trials will be critical when analyzing 
results to ensure that IDH1/2 mutant GBM patients do not 
confound interpretation of drug effectiveness on patient 
survival. 
Our study highlights that targeted exome sequencing 
of ALGGs performed in the clinical setting and CLIA-
certified environment provides valuable data, which can be 
used in lineage classification, to refine diagnoses made by 
light microscopy and provide mutational data, which may 
be valuable in selecting appropriate targeted therapies. 
METHODS 
Patient Selection
Analysis of data generated from tumor specimens 
and clinical variables was conducted following approval 
from the Dana-Farber/Brigham and Women’s Cancer 
Center (DF/BWCC) Institutional Review Board (IRB). 
Genotyping data from clinical OncoPanel testing reports 
was obtained from the medical record under a consented 
research protocol approved by the DF/BWCC IRB (11-
104). All sequencing assays were performed within the 
Molecular Diagnostics Division of the Brigham and 
Women’s Hospital Center for Advanced Molecular 
Diagnostics, a CLIA-certified laboratory environment. 
All tumors underwent central histopathologic re-
review using World Health Organization (WHO) criteria 
by two neuropathologists (J.B.C. and S.H.R.). Diagnosis 
of oligoastrocytomas required histologic evidence of 
astrocytic and oligodendroglial components, with the 
minor population representing >30% of tumor cells. In 
total, 108 brain tumors including 10 diffuse astrocytomas, 
18 anaplastic astrocytomas, 44 oligodendrogliomas grade 
II, 21 oligodendrogliomas grade III, 7 oligoastrocytomas 
grade II, and 8 oligoastrocytomas grade III were analyzed 
and included for this study. All tumors were analyzed for 
the presence of 1p/19q co-deletion detected by FISH, 
aCGH or copy number analysis from exome data. aCGH 
and FISH analyses were performed in the Cytogenetics 
Division of the Brigham and Women’s Hospital Center 
for Advanced Molecular Diagnostics, a CLIA-certified 
laboratory environmentOncotarget 8091 www.impactjournals.com/oncotarget
OncoPanel
DNA was isolated from 5-10 5µm FFPE slides 
containing at least 50% tumor nuclei using routine 
extraction methods previously described [23]. Somatic 
mutations in tumor DNA were detected using the exome-
sequencing platform OncoPanel (Illumina HiSeq) in 
the  DF/BWCC  CLIA-certified  laboratory  [24].  The 
OncoPanel assay detects mutations in 275 different cancer 
genes. The average time from tissue submission to report 
of data was six weeks. Figures 1, 3 and Supplemental 
Figure 1 were developed using a local instance of the 
MSKCC cBioPortal for Cancer Genomics software 
[25]. Oncopanel mutation datasets were reformatted and 
imported into a mysql database using cBio’s importer tool 
and then visualized using cBio’s OncoPrint module [25].
Immunohistochemistry
Diaminobenzidine (DAB), brightfield staining was 
performed according to standard protocols on five-micron 
thick  paraffin  sections  [26].  Antigens  were  retrieved 
using heat and 10 mM sodium citrate buffer (pH 6.0). 
The following primary antibodies were utilized: p53 
(ImmunoTech #1767), ATRX (Sigma, HPA001906), 
IDH1(R132H) (Dianova, DIA-H05). Counterstaining for 
nuclei was performed using Mayer’s hematoxylin stain 
and coverslips were mounted with Permount (Fisher 
Scientific).
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